Latest Regulatory Developments News

NobleOak Life Limited reported a robust 20% growth in in-force premiums and a 22% rise in underlying profit for FY25, surpassing guidance and setting a clear path to $1 billion in-force premium. Strategic partnerships, acquisitions, and product innovation underpin its strong outlook for FY26.

BTC Health Limited reported a remarkable 277% increase in profit after tax to nearly $4 million for FY25, driven by significant fair value gains on its healthcare investments and key contract wins.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

Reef Casino Trust and Iris Cairns Property Pty Ltd have agreed to increase the takeover bid price to $3.87 per unit, boosting the total offer value to approximately A$192.7 million. The unanimous board recommendation and major unitholder support underscore the deal’s momentum amid regulatory conditions.

Solvar Limited’s FY25 results highlight solid loan book growth in Australia, the strategic launch of Bennji commercial finance, and a significant 40% increase in dividends, underpinning confidence in future earnings.

Optiscan Imaging Limited has launched a $17.75 million fully underwritten entitlement offer to fund clinical trials, regulatory approvals, and product development. Peters Investments underwrites the offer, potentially increasing its stake to nearly 39%.

Basin Energy Limited has secured $1.25 million to advance exploration of uranium and rare earth metals across strategic Tier-1 jurisdictions, positioning itself amid rising global demand for clean energy minerals.

Horizon Oil and its partners have secured a ten-year extension for the Maari oilfield permit in New Zealand, enabling continued production and strategic planning through 2037. This comes as the field hits its highest output in over five years.

Neuren Pharmaceuticals reported a robust half-year with an 88% increase in net profit, driven by rising royalties from DAYBUE™ sales and progress in its NNZ-2591 clinical program. The company also completed a $39.6 million share buy-back, underscoring confidence in its growth trajectory.

Perpetual Credit Income Trust reported a 20.7% increase in net assets to $532.8 million for FY25, while posting a modest profit decline amid challenging market conditions. The Trust’s $93 million capital raise and diversified credit portfolio underpin its strategy for stable income and growth.

Coast Entertainment Holdings Limited reported a robust FY25 with record revenue and EBITDA growth, driven by strong visitor numbers and the successful launch of new attractions. The company’s momentum continues into FY26 amid ongoing macroeconomic challenges.

Regis Resources Limited delivered a standout FY25 with record revenue and profit, driven by unhedged gold sales and underground growth, while confronting a significant legal challenge over its McPhillamys Gold Project.